

## Supplementary Online Content

Bassi NS, Ziaeeian B, Yancy CW, Fonarow GC. Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. *JAMA Cardiol*. Published online May 6, 2020. doi:10.1001/jamacardio.2020.0898

### **eTable.** Randomized Clinical Trials

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable. Randomized Clinical Trials**

Benefits presented in Table 1 are derived from the following sources:

Evidence-Based Therapy	Source
ACEI/ARB	<ul style="list-style-type: none"> <li>• The SOLVD Investigators. Effect of enalapril in patients with reduced left ventricular ejection fractions and congestive heart failure. <i>N Engl J Med</i> 1991;325:293-302.</li> <li>• Garg R, Yusuf S. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. <i>JAMA</i> 1995;273:1450-6.</li> <li>• Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. <i>Lancet</i> 2000;355: 1575-81.</li> <li>• Fonarow GC, Yancy CW, Hernandez AF, et al. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. <i>Am Heart J</i>. 2011;161(6):1024-30.e3.</li> </ul>
ARNI	<p>McMurray JJV, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>N Engl J Med</i>. 2014; 371:993–1004.</p>
Beta-Blocker	<ul style="list-style-type: none"> <li>• MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). <i>Lancet</i> 1999;353:2001-7.</li> <li>• Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. <i>N Engl J Med</i> 2001;344:1651-8.</li> <li>• Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. <i>J Am Coll Cardiol</i> 1997;30:27-34.</li> <li>• Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure: a Bayesian meta-analysis. <i>Ann Intern Med</i> 2001;134: 550-60.</li> <li>• Fonarow GC, Yancy CW, Hernandez AF, et al. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. <i>Am Heart J</i>. 2011;161(6):1024-30.e3.</li> </ul>
Aldosterone Antagonist	<ul style="list-style-type: none"> <li>• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. <i>N Engl J Med</i> 1999;341:709-17.</li> <li>• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. <i>N Engl J Med</i> 2003;348:1309-21.</li> <li>• Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. <i>Eur Heart J</i> 2009;30:469-77.</li> </ul>

	<ul style="list-style-type: none"> <li>• Fonarow GC, Yancy CW, Hernandez AF, et al. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. <i>Am Heart J.</i> 2011;161(6):1024-30.e3.</li> </ul>
Hydralazine/Nitrate (in African-Americans)	Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. <i>N Engl J Med</i> 2004;351:2049-57
CRT	<ul style="list-style-type: none"> <li>• Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. <i>N Engl J Med</i> 2004;350:2140-50.</li> <li>• Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. <i>N Engl J Med</i> 2005;352:1539-49.</li> <li>• McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. <i>JAMA</i> 2007;297:2502-14.</li> <li>• Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, et al. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. <i>Eur Heart J</i> 2006;27:2682-8.</li> <li>• Fonarow GC, Yancy CW, Hernandez AF, et al. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. <i>Am Heart J.</i> 2011;161(6):1024-30.e3.</li> </ul>
ICD	<ul style="list-style-type: none"> <li>• Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. <i>N Engl J Med</i> 2002;346:877-83.</li> <li>• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. <i>N Engl J Med</i> 2005;352:225-37.</li> <li>• Desai A, Fang J, Maisel W, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. <i>JAMA</i> 2004;292: 2874-9.</li> <li>• Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. <i>Ann Intern Med</i> 2007;147:251-62.</li> <li>• Fonarow GC, Yancy CW, Hernandez AF, et al. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. <i>Am Heart J.</i> 2011;161(6):1024-30.e3.</li> </ul>
Transcatheter MVR	Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. <i>N Engl J Med.</i> 2018;379:2307-2318.
SGLT2-i	McMurray JJV, Solomon SD, Inzucchi SE, et al., for the DAPA-HF Trial Committee and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. <i>N Engl J Med</i> 2019; DOI: 10.1056/NEJMoa1911303.